NewMed Energy Profit Jumps 53% to $117 Million on Record Gas Output

NewMed Energy LP reported second-quarter 2026 net profit of $117 million, up 53% year over year, on record production and higher gas prices, while advancing its Leviathan and Aphrodite projects; the DKDRF over-the-counter listing last closed at 5.20, down 6.31% on the day, on Aug. 14, 2026.

NewMed Energy LP (OTC: DKDRF) told investors on its second-quarter 2026 earnings call that net profit rose 53% to $117 million, a result the partnership attributed to record production volumes and higher realized natural gas prices. It is the kind of quarter that usually reads as unambiguously good: more molecules sold, at better prices, through infrastructure that is already paid for.

The market's reaction was less enthusiastic. The over-the-counter DKDRF listing last traded at 5.20, down 6.31% from the prior close of 5.55, in a session that ranged between 5.20 and 5.41, according to market data as of 20:00 GMT on Friday, Aug. 14, 2026. That was a far heavier move than the broad benchmarks, which drifted: the S&P 500 tracker closed at $776.34, off 0.20%, the Nasdaq 100 tracker at $731.07, down 0.14%, and the Dow tracker at $536.80, down 0.21%.

What the 53% profit jump actually reflects

Two drivers were named on the call: volume and price. Both matter differently for a gas producer.

Volume gains at a record level suggest the underlying asset base is running harder than it has before — either because facility capacity has been debottlenecked, because more offtake has been contracted, or because seasonal and regional demand pulled more gas through the system. Volume growth of that kind tends to be durable. Once a producer proves it can sustain a higher plateau, the market usually assumes that plateau holds until something breaks.

Price is the softer half of the story. Higher realized gas prices flatter earnings in the quarter they occur and then vanish from the comparison the moment the market turns. Because the company reported profit growth without disclosing, in the material available, how much came from each factor, investors are left to guess the mix. That uncertainty is one plausible reason a 53% profit increase did not translate into a higher share price. The result was reported by GuruFocus from the company's earnings call.

Leviathan and Aphrodite are the real valuation questions

The two projects flagged as advancing — Leviathan and Aphrodite — carry more weight for a long-term holder than a single quarter's profit line does. Both sit in the eastern Mediterranean gas complex, where the commercial problem has never been finding gas. It has been moving it.

Leviathan is the anchor asset. Any expansion of its production or export capacity changes the arithmetic on how much gas NewMed can monetize and to whom — domestic power generation, regional pipeline customers, or, in the more ambitious formulations, liquefaction for seaborne export. Aphrodite adds a second resource base to that system, with the perennial complication that development economics depend on shared infrastructure and cross-border commercial arrangements rather than on drilling alone.

For a partnership structure, the sequencing question is blunt: capital goes out before gas comes in. Every quarter of record production helps fund the next phase of expansion internally rather than through debt or unitholder dilution. The $117 million profit figure is best read in that light — as fuel for the capital program as much as a reward to holders.

Why the stock fell on a good print

A 6.31% single-day decline against flat benchmarks is not a market-wide move. It is specific. Several explanations fit the facts as reported without requiring any of them to be true.

• Expectations were already high. If record production had been signaled ahead of the call, the print confirmed rather than surprised.
• Thin liquidity amplifies everything. An over-the-counter foreign listing typically trades in modest size, and modest size means small orders push prices further than they would on a primary exchange. The narrow session range — a low equal to the closing price — is consistent with selling into limited depth.
• Project timelines dominate. Investors in a development-heavy gas story care more about when Leviathan and Aphrodite volumes arrive than about last quarter's margin. Any hint of slippage outweighs a good number.
• Gas price gains cut both ways. Profit helped by price is profit the market discounts, because the same lever can reverse.

What holders of a foreign OTC listing should keep in mind

DKDRF is a secondary quotation, not the primary market for these units. That has practical consequences. Prices on the over-the-counter market reflect the primary listing's move plus a currency translation plus whatever spread local liquidity demands — which means a day's percentage change can overstate or understate what happened where the real volume trades. Reported profit in U.S. dollars, as here, does not remove that translation layer from the quote itself.

It also means disclosure arrives on the home market's calendar and in its format. Investors relying on U.S. filings will typically see less granular segment data than they would from a domestic producer of comparable size — including, in this case, a breakdown of how much of the 53% profit increase came from volume versus price.

The signposts that matter next

Three things will settle whether this quarter marks a turn or a peak.

First, whether record production is sustained into the second half. A record that stands alone is a strong quarter; a record that becomes the new baseline is a re-rating.

Second, firm dates and capital figures for Leviathan and Aphrodite. Vague progress language is standard on earnings calls. Committed spending, signed offtake and a sanctioned schedule are what move long-term cash flow models.

Third, the direction of realized gas prices. Because both named drivers pushed in the same direction this quarter, a reversal in price with flat volumes would compress profit quickly — and the reported 53% gain gives no guide to how much cushion exists.

For now the picture is a producer earning well from assets it already operates, spending to build the ones it does not yet, and trading at a level the market marked down on the day the good news landed. That gap between reported performance and share price reaction is the story worth following into the next report.

Key facts

• Q2 2026 net profit: $117 million, up 53% year over year
• Stated drivers: Record production volumes and higher natural gas prices
• DKDRF last close: 5.20, -6.31% (prev close 5.55), as of 20:00 GMT Aug. 14, 2026
• Projects advancing: Leviathan and Aphrodite

Frequently asked questions

How much did NewMed Energy earn in the second quarter of 2026?

NewMed Energy LP reported net profit of $117 million for the second quarter of 2026, a 53% increase from the prior-year period. The company attributed the improvement to record production volumes combined with higher realized natural gas prices, and said it was advancing its Leviathan and Aphrodite projects during the quarter.

Why did DKDRF shares fall if profit rose 53%?

The DKDRF listing last closed at 5.20, down 6.31% from the prior close of 5.55, on Aug. 14, 2026. No single reason was disclosed. Plausible factors include expectations already priced in, thin over-the-counter liquidity that amplifies moves, investor focus on project timelines rather than one quarter, and skepticism about profit driven partly by gas prices.

What are the Leviathan and Aphrodite projects?

Both are eastern Mediterranean natural gas assets in NewMed Energy's portfolio that the company said it is advancing. Leviathan is the anchor producing asset, and Aphrodite represents an additional resource base. Development economics for such projects depend heavily on shared export infrastructure and commercial offtake arrangements rather than drilling alone.

What does the DKDRF ticker represent?

DKDRF is an over-the-counter quotation in the United States for NewMed Energy LP units, rather than the partnership's primary listing. Prices on such secondary quotations reflect the home market's move plus currency translation plus local spread, so a day's percentage change may differ from where the bulk of trading volume occurs.

How did the broader market perform the same day?

Benchmarks were slightly lower on Aug. 14, 2026. The S&P 500 tracker closed at $776.34, down 0.20%; the Nasdaq 100 tracker at $731.07, down 0.14%; and the Dow 30 tracker at $536.80, down 0.21%. NewMed's 6.31% decline was therefore company-specific rather than a market-wide move.

What should investors watch next from NewMed Energy?

Three signposts: whether record production is sustained into the second half rather than being a one-quarter peak; firm capital figures and sanctioned schedules for Leviathan and Aphrodite; and the direction of realized natural gas prices, since both reported profit drivers moved in the same favorable direction this quarter.

Sources

• NewMed Energy LP (DKDRF) (Q2 2026) Earnings Call Highlights: Record Production and Strategic ... — GuruFocus

Photo: ZhiCheng Zhang · Pexels Licence — source